Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment. However, no studies have directly compared ...
Romosozumab is a US Food and Drug Administration-approved humanized monoclonal antibody used to treat osteoporosis in postmenopausal women with a high risk for fracture. The study included 70 adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results